Comparing high and standard dose flu vaccines for lung transplant patients
Comparison of High Dose vs. Standard Dose Influenza Vaccines in Lung Allograft Recipients
This study is looking at whether a stronger flu vaccine works better than the regular one for people who have had a lung transplant, since they are more likely to get really sick from the flu, and we want to find the best way to protect them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11036263 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of high-dose versus standard-dose influenza vaccines specifically in lung transplant recipients, who are at a higher risk for severe influenza due to their immunosuppressed state. The study aims to determine if a higher dose of the vaccine can elicit a better immune response compared to the standard dose, especially during the critical early post-transplant period. Participants will receive either the high-dose or standard-dose vaccine, and their immune responses will be monitored to assess safety and efficacy. The goal is to improve vaccination strategies for this vulnerable population to reduce the risk of influenza-related complications.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung transplant recipients who are within the early post-transplant period and are at risk for influenza.
Not a fit: Patients who are not lung transplant recipients or those who are not currently in the early post-transplant period may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccination protocols that enhance protection against influenza for lung transplant recipients.
How similar studies have performed: Previous studies have shown promising results with high-dose influenza vaccines in solid organ transplant recipients, indicating potential for success in this specific population.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Halasa, Natasha Bassam — Vanderbilt University Medical Center
- Study coordinator: Halasa, Natasha Bassam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.